Skip to main content
OpenTrials
Completed

NCT Number: NCT02492217

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

To identify new candidate genes and proteins that are differentially expressed in responders' vs non-responders to anti-TNF alpha therapy at the several time points the investigators will use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and protein markers regarding prediction to anti-TNF alpha therapy efficacy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Faculdade de Ciências Médicas da Universidade Nova de Lisboa

Lisbon, Portugal

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • AS according to Portuguese Society of Rheumatology (SPR) guidelines (1984 modified New York Criteria, but allowing the use of MRI as imagiological criteria)
  • Patient enrolment followed national guidelines for TNF antagonist use for the treatment of AS
  • Adults between 18 to 75 years
  • Ability to provide informed consent
  • Corticosteroid therapy allowed (equivalent to ≤ 10 mg prednisone) and / or NSAID(nonsteroidal antiinflammatory drug), stable dose in 4 weeks before study initiation
  • Adequate contraception (barrier or hormonal) in men and women of childbearing age (patients and their partners
  • Adequate renal and hepatic function (2 times ULN)

Exclusion criteria

  • Current pregnancy or breastfeeding
  • Previous treatment with biologic DMARD's (disease-modifying antirheumatic drug)
  • Intraarticular injections or infiltrations of extraaxial joints and tendons within 28 days before or at screening, or intraarticular injections of sacroiliac joints ≤ 28 days before screening
  • History of rheumatic disorder other than AS
  • Other forms of spondylarthritis than AS
  • Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable ischemic heart disease)
  • History or signs of demyelinating disease
  • Malignancy (except for completely treated squamous or basal cell carcinoma)
  • Moderate to severe heart failure (NYHA class III/IV) Positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus
  • Active or latent tuberculosis (TB) or histoplasmosis or other severe infections such as sepsis, and opportunistic infections
  • Infections requiring hospitalization or intravenous treatment with antibiotics within 30 days or oral treatment with antibiotics within 14 days before enrollment
  • Ankylosis of the spine (syndesmophytes presence at all levels from D12 to S1 in X-ray (XR) lateral view)
  • Hypersensitivity to the active substance or to any of the excipients

Treatment and study plan

Adalimumab

Drug

Primary outcomes

  1. Clinical response biomarkers (Assessment of Spondyloarthritis International Society (ASAS) 20 and Ankylosing Spondylitis Disease Activity Score (ASDAS)

    Time frame: 14 weeks

    To identify anti-TNF alpha clinical response biomarkers by microarrays and proteomics technology.

Secondary outcomes

  1. QoL evaluation

    Time frame: 14 weeks

    To evaluate quality of life using ASQOL and SF-36 questionnaires

  2. MRI progression

    Time frame: 14 weeks

    Rachis evaluation according to acute and structural lesions

Sponsors and collaborators

Lead sponsor

Universidade Nova de Lisboa

Other

Registry information

Official study title

Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Jul 8, 2015
Registry last updated
Nov 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.